

1 **Prevalence of IgG antibodies against SARS-CoV-2 among healthcare workers in a tertiary pediatric**
2 **hospital in Poland**

3

4 Beata Kasztelewicz^{1*}, Katarzyna Janiszewska¹, Julia Burzyńska¹, Emilia Szydłowska¹, Marek Migdał²,
5 Katarzyna Dzierzanowska-Fangrat¹

6

7 ¹ Department of Clinical Microbiology and Immunology, The Children's Memorial Health Institute, Warsaw,
8 Poland

9 ² Department of Anaesthesiology and Intensive Care, The Children's Memorial Health Institute, Warsaw, Poland

10

11

12

13 ***Corresponding author**

14 b.kasztelewicz@ipczd.pl (BK)

15

16 **Abstract**

17 Data on prevalence of SARS-CoV-2 antibody in healthcare workers (HCWs) is scarce, especially in pediatric
18 settings. The purpose of this study was to evaluate the SARS-CoV-2 IgG-positivity among HCWs of a tertiary
19 pediatric hospital. In addition, follow-up of serological response in the subgroup of seropositive HCWs was
20 performed, to get some insight on persistence of IgG antibodies to SARS-CoV-2. Free, voluntary SARS-CoV-2
21 IgG testing was made available to HCWs of the Children's Memorial Health Institute in Warsaw (Poland).
22 Plasma samples were collected between July 1 and August 9, 2020 and tested using the Abbott SARS-CoV-2
23 IgG assay. Of 2282 eligible participants, 1879 (82.3%) HCWs volunteered to undergo testing. Sixteen HCWs
24 tested positive for SARS-CoV-2 IgG, corresponding to the seroprevalence of 0.85%. Among seropositive
25 HCWs, three had confirmed COVID-19. Of note, 8 (50%) seropositive HCWs reported neither symptoms nor
26 unprotected contact with confirmed SARS-CoV-2 cases in the previous months. A decline in the IgG index was
27 observed at median time of 86.5 days (range:84-128 days) after symptom onset or RT-PCR testing. The
28 nationwide public health response measures together with infection prevention and control practices
29 implemented at the hospital level, at the beginning of the COVID-19 pandemic, might explain a low
30 seroprevalence. Further studies are warranted to elucidate the duration of anti-SARS-CoV-2 antibodies, as well
31 as the correlation between seropositivity and protective immunity against reinfection. Regardless of the
32 persistence of antibodies and their protective properties, such low prevalence indicates that this population is
33 vulnerable to a second wave of the COVID-19 pandemic.

34

35 **Introduction**

36 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing coronavirus disease 2019 (COVID-
37 19) which emerged in December 2019, has evolved to a global pandemic [1]. In Poland first, imported COVID-
38 19 case was reported on March, 3 2020 and 3 weeks later a nationwide lockdown was commenced [2]. Until
39 August, 31, there were 66 870 confirmed cases, with 2 033 COVID-19 related deaths [3].

40 In the Masovian district (one of the three most affected regions in Poland) the first cases were recorded on
41 March 13 and by the end of August 2020, there were 9370 cases and 411 deaths [4].

42 Although real-time RT-PCR is considered the gold standard for the diagnosis of the acute SARS-CoV-2
43 infection, this test is limited by transient nature of RNA. In addition, the sensitivity of RT-PCR methods is
44 estimated to be no higher than 70% [5], which may lead to underdiagnosing of SARS-CoV-2 infections,
45 especially in subclinical or asymptomatic cases. By identifying individuals who have developed antibodies to the
46 virus (including those that may be asymptomatic or have recovered), serology can give greater details into the
47 prevalence of SARS-CoV-2. Although, concerns have arisen on persistence of IgG antibodies to SARS-CoV-2
48 after recovery [6,7].

49 Two entities of infected individuals pose the highest risk for SARS-CoV-2 transmission in the hospital setting.
50 First, infected patients until diagnosis. Second, SARS-CoV-2-positive health care workers (HCWs). As children
51 and adolescent comprise less than 5% of all positive cases in Europe [8], majority of SARS-CoV-2 infections
52 among HCWs in pediatric hospitals might be associated with transmission in community or from infected co-
53 workers.

54 Data on SARS-CoV-2 prevalence among HCWs in pediatric hospital settings is scarce [9,10].

55 Knowing the prevalence of SARS-CoV-2 infection among HCWs is vital to inform pandemic response. The aim
56 of this study was to evaluate the SARS-CoV-2 IgG positivity among HCWs of a tertiary pediatric hospital in
57 Warsaw (Masovian district), Poland. In addition, we have performed follow-up of serological response to SARS-
58 CoV-2 in the subgroup of seropositive HCWs, to get some insight on persistence of specific antibodies.

59

60 **Materials and methods**

61 Free, voluntary SARS-CoV-2 IgG testing was made available to the hospital staff of the Children's Memorial
62 Health Institute (CMHI) in Warsaw, Poland (including physicians, nurses, other workers with direct patient
63 contact, i.e. physical therapists as well as workers without direct patient contact, i.e. laboratory workers,

64 pharmacists, administrative staff, maintenance, etc.). All participants were asymptomatic at the time of serology
65 testing. In particular, those who were previously symptomatic, had no symptoms for at least 14 days. Plasma
66 (EDTA) samples were collected between July 1 and August 9, 2020 (corresponding to 97 – 135 days after the
67 nation-wide lockdown was commenced).

68 Plasma samples were run on the Abbott Alinity i instrument using the Abbott SARS-CoV-2 IgG assay (Abbott
69 Laboratories, Lake Bluff, IL, USA) following manufacturer's instruction. The assay is a chemiluminescent
70 microparticle immunoassay (CMIA) for qualitative detection of IgG antibodies to the nucleocapsid (N) protein
71 of SARS-CoV-2. The manufacturer's index value (a signal/cut-off; S/CO ratio) of ≥ 1.40 was interpreted as
72 positive. The assay has been shown to have 99.9% specificity and 100% sensitivity for samples taken greater
73 than 17 days post symptom onset [11].

74 Demographic data (age, gender), results of SARS-CoV-2 RNA testing (if performed in CMHI) were collected
75 for all participants, from the laboratory records. Data on profession and the necessity of quarantine or isolation
76 (date and duration of quarantine or isolation) were collected from human resource's database. In addition,
77 seropositive or previously SARS-CoV-2 infected individuals were approached telephonically and data regarding
78 contacts with a confirmed or suspected COVID-19 case, the positive test result in the past (if performed outside
79 CMHI), the necessity of inpatient treatment, experienced symptoms over the previous months, were collected by
80 the head of the infection control department. All data were analyzed anonymously.

81

82 **Study setting**

83 The CMHI in Warsaw (Masovian district), is the largest tertiary pediatric hospital and research institute in
84 Poland. With over 590 beds and 2282 employees it performs over 249 000 services (including inpatients and
85 outpatients) per year.

86 At the time of serology testing, we had no case of SARS-CoV-2 infection among patients. Until July1, 2020, the
87 first day of the serology testing, we had had 5 confirmed SARS-CoV-2 infections among HCWs (all contracted
88 outside the hospital setting, one confirmed outside CMHI) and there were no additional cases until July 6, 2020.
89 Since that time until August 9, 2020 (i.e. the end of the serology testing), additional 4 linked cases among
90 laboratory staff, were confirmed by RT-PCR (**Fig 1**).

91

92 **Figure 1.** The epidemic curve is shown as the number of HCWs tested each week for SARS-CoV-2 RNA by
93 RT-PCR in CMHI together with the number of new SARS-CoV-2 cases recorded in the Masovian district. The

94 first case of SARS-CoV-2 RNA among HCWs of CMHI was detected on March, 17 2020. Voluntary serological
95 testing for HCWs of CMHI was conducted from July 1 to August 9, 2020 (corresponding to week 27 and 32).
96 Details of infection prevention and control measures implemented at CMHI together with the nationwide
97 lockdown, are given below the curve.

98

99 **Statistical analysis**

100 Statistical analysis was carried out using the Statistica data analysis software system (TIBCO Software Inc.),
101 version 13. Continuous variables were presented as median and interquartile range (IQR). Categorical variables
102 were summarized using percentages and counts. Seroprevalence of SARS-CoV-2 IgG was calculated as
103 proportion with 95% confidence intervals (CI). The association between variables was tested with Chi-square or
104 Fisher's exact test (for categorical variables) and Mann Whitney U test (for continuous variables). Univariable
105 and multivariable logistic regression analysis were run to evaluate factors associated with seroprevalence of
106 SARS-CoV-2 IgG. For the variables to be included in multiple logistic model, a stepwise selection was used,
107 starting with the full model, and using p-value of 0.1 for removal and 0.05 for addition of variables.

108

109 **Ethical consideration**

110 This study reporting the results of free-voluntary serology testing, was not offered as a research protocol but as a
111 service to healthcare workers. The study has been reviewed and approved by the Institutional Review Board of
112 the Children's Memorial Health Institute in Warsaw (Ref. no. 10/P-IN/20), and granted a waiver of consent since
113 the data were analyzed anonymously.

114

115 **Results**

116 **Baseline characteristics**

117 Of 2282 eligible participants, 1879 HCWs volunteered to undergo testing, yielding a participation rate of 82.3%.
118 Median (IQR) age was 48 (38-56) years, and 85.8% were female. Approximately one third (639/1879, 34%)
119 were nurses, and 19.7% were physicians.

120 Majority (70.9%) of HCWs worked in the clinical area. Twenty-two per cent (417/1879) had been tested for
121 SARS-CoV-2 RNA by RT-PCR as a part of implemented infection control measurements (note that

122 administration of RT-PCR test does not imply that a HCW was suspected of having COVID-19, since tests were
123 also performed as a part of contact tracing, in previously quarantined or isolated HCWs before return to work or
124 in newly employed staff). The median time between RT-PCR and serology testing was 77 days (IQR: 39-122
125 days). SARS-CoV-2 RNA was detected in 4 of 417 HCWs, including 3 HCWs with positive serology (details
126 given below). The remaining one, with a positive SARS-CoV-2 RNA test, was seronegative. This was the HCW
127 whose plasma was collected 129 days post RT-PCR testing.

128 Fifty-six HCWs had been quarantined or isolated. The median time since the start of quarantine or isolation to
129 serology testing was 97.5 days (IQR: 42.5-126 days) (Table 1).

130 **Table 1.** Baseline characteristics of 1879 HCWs.

131

Characteristics	Total (%)
Sex:	
male	266 (14.2)
female	1613 (85.8)
Age, median (IQR) years	48 (38-56)
Professional category: ^a	
nurse	639 (34.0)
physician	371 (19.7)
other with a direct patient contact	226 (12.0)
other without a direct patient contact	643 (34.2)
Healthcare department: ^b	
clinical	1332 (70.9)
non-clinical	547 (29.1)
Previously tested for SARS-CoV-2 RNA	
yes ^c	417 (22.2)
no	1462 (77.8)
Quarantined or isolated:	
yes ^d	56 (3.0)
no	1823 (97.0)

132 ^a*other with a direct patient contact*: patient care technician (67); physical therapist (43), radiation therapist (37);
133 psychologist (21), medical assistant (11), audiologist (10), pedagogue (9), speech pathologist (8), clinic engineer
134 (6), medical technician (6), dentist assistant (4), anthropologist (4); *other without a patient contact*: office
135 worker (228), secretary (136), laboratory worker (110), kitchen worker (34), pharmacist (32), dietician (27),
136 medical sterilization technician (19); driver (17), labourer (15), store man (8), IT worker (7), public health
137 worker (3), manager (2); security officer (2), chaplain (2), parking attendant (1).

138 ^b*clinical departments* include: medical (765), surgical (222), auxiliary medical (123), ambulatory (116),
139 intensive care (106); *non-clinical departments* include: administration (284), laboratory (113), maintenance
140 (116), pharmacy (34).

141 ^c median period between SARS-CoV-2 RNA and serology testing was 77 days (range 1 – 136 days; IQR 39-122
142 days); 4 out of 417 (0.96) HCWs had positive test results.

143 ^d median period between the start of quarantine/isolation and serology testing was 97.5 days (range 10 -133 days;
144 IQR 42.5-126 days).

145 **Seroprevalence among HCWs**

146 Sixteen healthcare workers tested positive for SARS-CoV-2 IgG, corresponding to the seroprevalence of 0.85%.

147 Median index was 2.69 S/CO (range: 1.41-7.59 S/CO).

148 Of the 16 seropositive HCWs, only 3 (18.75%) tested positive for SAR-CoV-2 RNA (within the prior 53-106
149 days). Five seropositive HCWs were RT-PCR negative within the prior 6-127 days (only one of them had been
150 tested less than 14 days prior to serology). The remaining eight seropositive HCWs had not been tested by RT-
151 PCR (all of them were negative, when tested 1-11 days after IgG testing).

152 Among seropositive HCWs, six (37.5%) presented symptoms compatible with COVID-19, one had a household
153 contact with a suspected COVID-19 case, whereas 8 (50%) reported neither symptoms compatible with COVID-
154 19 in the prior months nor unprotected close contacts with confirmed or suspected COVID-19 cases (**Table 2**).

155 **Table 2.** Characteristics of the seropositive HCWs.
156

No.	Age (years)	Gender	SARS-CoV-2 IgG (S/CO)	SARS-CoV-2 RNA by RT-PCR	Time since RT-PCR testing and serology testing	Symptoms compatible with COVID-19	Possible route of SARS-CoV-2 transmission
1	50	f	3.07	negative	2 days*	no	unknown
2	45	f	1.85	negative	2 days*	no	unknown
3	60	f	1.52	negative	11 days*	no	unknown
4	60	f	1.41	negative	6 days	no	unknown
5	60	f	5.00	positive	43 days	yes	household contact with a confirmed case
6	50	f	1.66	negative	3 days*	no	unknown
7	50	f	6.92	negative	1 day*	no	household contact with a suspected case
8	45	f	2.04	(multiple) negative	14, 34, 42, 111 days	yes	unknown
9	40	f	2.42	(multiple) negative	62, 127 days	no	unknown
10	55	m	2.86	positive	106 days	yes	unknown
11	55	f	4.32	negative	82 days	no	unknown
12	40	f	2.51	negative	within 24 h*	no	unknown
13	50	f	3.76	positive	53 days	yes	unknown
14	60	f	7.59	negative	14 days	yes	unknown
15	65	m	2.21	negative	2 days*	no	unknown
16	50	f	7.32	negative	within 24 h	yes	unknown

157 * indicates HCWs who were tested by RT-PCR after serology testing results were obtained.

158 **Factors associated with SARS-CoV-2 IgG positivity**

159 The odds of being seropositive were higher in HCWs who had been previously tested by RT-PCR regardless of
160 the test results (adjusted OR=3.82, 95% CI: 1.42-10.29; p=0.008) (**Table 3**). The age, sex, professional category
161 or working in clinical area, did not show any statistically significant association with the positivity for SARS-
162 CoV-2 IgG (**Table 3**).

Table 3. Analysis of factors associated with SARS-CoV-2 IgG positivity.

Characteristics	SARS-CoV-2 IgG		P-value ^a	Univariate		Multivariate	
	negative	positive		OR (95% CI)	P-value	OR (95% CI)	P-value ^c
Sex:			0.849		0.849		
male	264 (14.2)	2 (12.5)		1			
female	1599 (85.8)	14 (87.5)		1.16 (0.26 – 5.11)			
Age, median (IQR) years ^b	48 (38-56)	50.5 (46-57.5)	0.141	1.03 (0.99 – 1.08)	0.131	1.04 (0.99 – 1.09)	0.093
Professional category:			0.114				
other without a direct patient contact	639 (34)	4 (25)		1			
nurse	635 (34)	4 (25)		1.01 (0.25 – 4.04)	0.992		
physician	364 (20)	7 (44)		3.07 (0.89 – 10.56)	0.075		
other with a direct patient contact	225 (12)	1 (6)		0.71 (0.08 – 6.39)	0.760		
Healthcare department:			0.716		0.717		
non-clinical	543 (29)	4 (25)		1			
clinical	1320 (71)	12 (75)		1.23 (0.40 – 3.84)			
Previously tested for SARS-CoV-2 RNA			0.007		0.012		0.008
no	1454 (78.05)	8 (50)		1			
yes	409 (21.95)	8 (50)		3.56 (1.33 – 9.53)		3.82 (1.42-10.29)	

^aChi-squared test

^bMann Whitney U test

^cWald tes

Follow up serological data

Three (i.e. no. 5, 11 and 14) out of 16 seropositive HCWs provided second sample for serology testing. Time span between initial testing and the second sample was 36 (no.11), 57 (no. 14) and 85 (no. 5) days, which corresponds to 88, 118 and 128 days, post symptom onset (no. 5 and 14) or RT-PCR testing (no. 11). Decrease in SARS-CoV-2 IgG index value was observed in all 3 cases.

In addition, we monitored three initially seronegative HCWs, diagnosed with COVID-19 within a week following their first serology testing (i.e. in the week 27). All three were epidemiologically linked and thus considered clustered cases with intra-hospital transmission. These HCWs were immediately put on home isolation as soon as they were identified by RT-PCR testing (all experienced mild symptoms). After their return to work, SARS-CoV-2 IgG was tested twice in convalescent plasma samples collected 34-37 and 84-85 days after the RT-PCR testing. Decrease in the index value were observed in all 3 cases between the second and the third month after symptom onset.

Overall, all six HCWs remained seropositive while tested on the last sample collected at the median time of 86.5 days (range: 84-128 days) after symptom onset or RT-PCR testing (**Fig 2**).

Figure 2. SARS-CoV-2 IgG follow-up data in 6 HCWs including three seropositive at initial testing (no. 5, 11 and 14) and three HCWs clustered cases (indicated by #), who had confirmed COVID-19 within a week following initial serology testing (in the week 27). The dashed line indicates positivity threshold (1.4 S/CO).

Discussion

In Poland, a nationwide lockdown, including closure of school, public institutions, and mandatory face-mask was implemented during the very early stages of the COVID-19 pandemic [2]. As a result, the daily numbers of new SARS-CoV-2 infections have been relatively stable up to the study period with cumulative incidence of 90.6 per 100 000 as on July 1 2020. Preceding nationwide public health response measures, a set of infection prevention and control measures had been implemented in CMHI, to contain the spread of SARS-CoV-2 infection within the hospital. These included (but were not limited to): measurement of body temperature at the hospital entry, patient/caretaker screening for SARS-CoV-2 RNA by RT-PCR on nasopharyngeal swabs on admission and RT-PCR testing of all symptomatic staff coupled with contact tracing.

Seroprevalence studies in HCWs allow for assessing the level of exposure, and indirectly, the effectiveness of implemented protective measures. They are also crucial to inform health care resource planning to provide safe environment to protect both patients and HCWs from SARS-CoV-2 infection. A few seroprevalence studies of HCWs in pediatric hospitals have been published so far. Here, we present the results of serology testing in HCWs of the large pediatric hospital in Poland, including over 82% of employees. In our study SARS-CoV-2 IgG positivity rate was 0.85%, and it was lower than in previous reports from pediatric hospitals. The seroprevalence of SARS-CoV-2 among 175 HCWs in a large referral pediatric hospital in Barcelona was 4% [10]. Another study from Italy, performed at the same time (i.e. mid-April 2020), showed seroprevalence of 5.13% [12]. Timing of serology testing (April 2020 vs July 2020) and significantly higher burden of COVID-19 (as Spain and Italy were two most affected countries in Europe, [13]) may account for this difference. In addition, and in contrast to Spanish and Italian reports, we did not have any confirmed COVID-19 case among patients in our hospital until the end of the study period.

Interestingly, we did not observe any difference in seroprevalence between clinical and non-clinical working locations or across professional groups. This may be due to the fact that at that time we did not managed any children with confirmed COVID-19. Although asymptomatic SARS-CoV-2 carriage among hospitalized children cannot be completely ruled out (since RT-PCR screening on admission is not 100% sensitive to preclude infection), the risk of children to staff transmission seems to be low. The recent study from pediatric hospital in Chicago, revealed a low (1-2 %) prevalence of SARS-CoV-2 among children without COVID-19 symptoms as well as no secondary transmission among HCWs exposed to these patients [14]. Another study, comparing dynamics and determinants of SARS-CoV-2 transmissions among HCWs of adult and pediatric settings in Paris, revealed significantly lower attack rate in the pediatric setting (2.3% vs 3.2%, respectively) [15].

In our study, prior RT-PCR testing regardless of the result, was associated with increased adjusted risk of SARS-CoV-2 IgG positivity. This may be a reflection of the fact that, testing for SARS-CoV-2 RNA was performed as a part of contact tracing and in previously quarantined or isolated HCWs before return to work. Considering that as many as 50% of seropositive HCWs in our study were asymptomatic or had no confirmed contact with suspected or proven COVID-19 case, and that over 80% (13/16) had not been tested or tested negative for SARS-CoV-2 RNA, it could indicate that some SARS-CoV-2 infections among HCWs were unrecognized or undetected. Although, false-positive SARS-CoV-2 IgG results are possible (e.g. due to cross-reactivity to commonly circulating human coronaviruses) they are unlikely, even in the limited circulation of the virus [11].

Thus, it seems reasonable to test both symptomatic and asymptomatic HCWs for SARS-CoV-2 RNA on a regular basis, if resources are available.

We evaluated antibody persistence in a subgroup of HCWs with multiple plasma samples available for serology testing, to get some insight into antibody persistence. SARS-CoV-2 IgG antibodies were detected up to 128 days post symptoms onset or RT-PCR testing. However, the index value declined consistently in all subjects between first and last plasma sample tested. Our findings are in line with some previously published data on kinetics of SARS-CoV-2 IgG [16,17]. Recent study by Strömer et al. evaluated SARS-CoV-2 IgG levels in follow-up samples from 16 individuals (median time of the last sample submission was 153 days after the RT-PCR) and revealed that several SARS-CoV-2 infected patients lost their N-specific IgG within a few months or could lose them soon [16]. Of note, in contrast to N-specific IgG, the response to the spike (S) protein was found to be more stable and was associated with the presence of virus-neutralizing antibodies (although at relatively low titres). Another study by Patel et al., evaluated change in antibodies to SARS-CoV-2 over 60 days among 19 HCWs (including symptomatic ones), using S-based assay [17]. They observed a decrease in anti-SARS-CoV-2 antibodies in all HCWs, with 58% of seropositive individuals becoming seronegative. Taking together, these findings suggest that seroprevalence studies may underestimate rates of prior infections as antibodies may only be transiently detectable after infection. Nevertheless, the limited number of HCWs with follow-up sample available precludes any meaningful conclusion. In contrast to ours and two studies mentioned above, a recent population-based study, implementing two highly sensitive and specific assays to monitor antibody levels and their durability, indicated that antibody remained stable over 4 months. These discordant results may be attributed to sampling biases [18]. Thus, larger longitudinal serological studies are warranted, including these with virus neutralization assays, to explore the dynamic and the persistence of the SARS-CoV-2 antibodies as well as their correlation with immunoprotection from reinfection.

Our study has some limitations which should be acknowledged. First, testing spanned an over a 5-week period (week 27 – 32), potentially leading to changes in incidence over time and possible variation in professional groups attending testing. Second, we cannot rule out that some of HCWs were infected and either mounted no detectable antibody response or it had waned by the time of serology testing, as we had found one of confirmed COVID-19 case seronegative 129 days after the positive RT-PCR test. Thus, the seroprevalence in our study could be underestimated. Moreover, data on symptoms, exposure histories or personal protective equipment use were collected only for the subset of seropositive HCWs by telephone interview (subjected to recall bias), therefore more detailed information on risk factors could not be assessed. Nevertheless, so far this is the largest

study assessing the prevalence of SARS-CoV-2 IgG antibodies among HCWs in the pediatric hospital setting, with a high response rate and the use of high-quality serological assay. Our study provides data on the seroprevalence of SARS-CoV-2 infection among HCWs in the pediatric setting in the initial peak of the pandemic, which inform control and prevention strategies for future waves of COVID-19 pandemic.

Conclusions

SARS-CoV-2 seroprevalence in healthcare workers of a tertiary pediatric hospital in Poland is low (0.85%). The nationwide public health response measures together with infection prevention and control practices implemented at the hospital level, at a start of COVID-19 pandemic, might explain a low seroprevalence. Further studies are warranted to elucidate the duration of anti-SARS-CoV-2 antibodies, as well as the correlation between seropositivity and protective immunity against reinfection. Regardless of the persistence of antibodies and their protective properties, such low prevalence indicates that this population is vulnerable to a second wave of COVID-19 pandemic.


References

1. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. [cited 27 Oct 2020]. Available: <https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020>
2. Week 42, 2020. [cited 26 Oct 2020]. Available: https://covid19-country-overviews.ecdc.europa.eu/#27_poland
3. WHO. WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard. In: Who [Internet]. 2020 [cited 27 Oct 2020]. Available: https://covid19.who.int/%0Ahttps://covid19.who.int/region/wpro/country/cn%0Ahttps://covid19.who.int/?gclid=CjwKCAjwztL2BRATEiwAvnALcpJvfJoB2ZO9AW4cscOjOPpuNNisqVVITkpdslGJOuXSFkrhbLCafxoCjB0QAvD_BwE%0Ahttps://covid19.who.int/region/amro/country/br
4. Komunikat MPWiS z dnia 31 sierpnia 2020 r., przedstawiający sytuację epidemiologiczną na terenie województwa mazowieckiego związaną z koronawirusem SARS-CoV-2 wywołującym zachorowania na COVID-19. - WSSE. [cited 27 Oct 2020]. Available: <http://wsse.waw.pl/aktualnosci-i-komunikaty/komunikaty/komunikat-mpwis-z-dnia-31-sierpnia-2020-r-przedstawiajacy-sytuacje->

epidemiologiczna-na-terenie-województwa-mazowieckiego-zwiazan

5. Woloshin S, Patel N, Kesselheim AS. False Negative Tests for SARS-CoV-2 Infection — Challenges and Implications. *N Engl J Med*. 2020;383: e38. doi:10.1056/NEJMp2015897
6. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat Med*. 2020;26: 1200–1204. doi:10.1038/s41591-020-0965-6
7. Ibarondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. *N Engl J Med*. 2020;383: 1085–1087. doi:10.1056/nejmc2025179
8. COVID-19 in children and the role of school settings in COVID-19 transmission. [cited 26 Oct 2020]. Available: <https://www.ecdc.europa.eu/en/publications-data/children-and-school-settings-covid-19-transmission>
9. Amendola A, Tanzi E, Folgori L, Barcellini L, Bianchi S, Gori M, et al. Low seroprevalence of SARS-CoV-2 infection among healthcare workers of the largest children hospital in Milan during the pandemic wave. *Infect Control Hosp Epidemiol*. 2020; 1. doi:10.1017/ice.2020.401
10. Dacosta-Urbieta A, Rivero-Calle I, Pardo-Seco J, Redondo-Collazo L, Salas A, Gómez-Rial J, et al. Seroprevalence of SARS-CoV-2 Among Pediatric Healthcare Workers in Spain. *Front Pediatr*. 2020;8: 547. doi:10.3389/fped.2020.00547
11. Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, et al. Performance characteristics of the abbot architect sars-cov-2 igg assay and seroprevalence in Boise, Idaho. *J Clin Microbiol*. 2020;58. doi:10.1128/JCM.00941-20
12. Amendola A, Tanzi E, Folgori L, Barcellini L, Bianchi S, Gori M, et al. Low seroprevalence of SARS-CoV-2 infection among healthcare workers of the largest children hospital in Milan during the pandemic wave. *Infect Control Hosp Epidemiol*. 2020; 1. doi:10.1017/ice.2020.401
13. Coronavirus Disease (COVID-19) Situation Reports. [cited 26 Oct 2020]. Available: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>
14. Patel AB, Clifford A, Creaden J, Kato K, Malakooti MR, Muller WJ, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Point Prevalence Among Asymptomatic Hospitalized Children and Subsequent Healthcare Worker Evaluation. *J Pediatric Infect Dis Soc*. 2020 [cited 26 Oct 2020]. doi:10.1093/jpids/piaa102
15. Contejean A, Leporrier J, Canouï E, Alby-Laurent F, Lafont E, Beaudeau L, et al. Comparing Dynamics

- and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 Transmissions Among Healthcare Workers of Adult and Pediatric Settings in Central Paris. *Clin Infect Dis*. 2020 [cited 26 Oct 2020]. doi:10.1093/cid/ciaa977
16. Strömer A, Rose R, Grobe O, Neumann F, Fickenscher H, Lorentz T, et al. Kinetics of Nucleo- and Spike Protein-Specific Immunoglobulin G and of Virus-Neutralizing Antibodies after SARS-CoV-2 Infection. *Microorganisms*. 2020;8: 1572. doi:10.3390/microorganisms8101572
 17. Patel MM, Thornburg NJ, Stubblefield WB, Talbot HK, Coughlin MM, Feldstein LR, et al. Change in Antibodies to SARS-CoV-2 over 60 Days among Health Care Personnel in Nashville, Tennessee. *JAMA - Journal of the American Medical Association*. American Medical Association; 2020. doi:10.1001/jama.2020.18796
 18. Alter G, Seder R. The Power of Antibody-Based Surveillance. *N Engl J Med*. 2020 [cited 26 Oct 2020]. doi:10.1056/nejme2028079



Lock-down

- March 17: RT-PCR (TAT 4-8 h) for all symptomatic patients and HCWs with contact tracing, May 18: RT-PCR for all admitted patients and their caregivers
- All regular nonurgent patient care cancelled
- Risk-based PPE risk-based personal protective equipment (PPE) hospital policy for HCWs in clinical area
- Mandatory facemask use in all hospital area
- Separate entrance and patient flow for patient with symptoms compatible with COVID-19
- Temperature measurement at hospital entry

